{"id":521689,"date":"2021-08-02T17:03:08","date_gmt":"2021-08-02T21:03:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"modified":"2021-08-02T17:03:08","modified_gmt":"2021-08-02T21:03:08","slug":"scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","title":{"rendered":"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ:\u00a0SCYX<\/a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS common stock at a per share exercise price of $6.97, the closing trading price on July 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS\u2019 offers of employment.<\/p>\n

Each option has a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the employee\u2019s first date of employment and the remainder vesting in equal monthly installments for thirty-six months thereafter, provided the employee continues to provide service to SCYNEXIS. The stock options were granted pursuant to SCYNEXIS\u2019 2015 Inducement Award Plan, as amended, which was adopted by SCYNEXIS\u2019 board of directors under Rule 5635(c)(4) for equity grants to induce new employees to enter into employment with SCYNEXIS.<\/p>\n

\n About\u00a0SCYNEXI
<\/strong>SCYNEXIS, Inc.\u00a0(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. We are developing our lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The New Drug Application (NDA) for BREXAFEMME\u00ae<\/sup> (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visit\u00a0www.brexafemme.com<\/a>. We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visit\u00a0www.scynexis.com<\/a>.\u00a0
<\/strong><\/p>\n

\n
\n CONTACT<\/u>
\n <\/strong>
\n :\u00a0<\/strong>
\n
\n Investor Relations<\/strong>
\n
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com<\/a><\/p>\n

\n Media Relations<\/strong>
\n
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ:\u00a0SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS common stock at a per share exercise price of $6.97, the closing trading price on July 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS\u2019 offers of employment. Each option has a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the employee\u2019s first date of employment and the remainder vesting in equal monthly installments for thirty-six months … <\/p>\n

Continue reading “SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521689","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ:\u00a0SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS common stock at a per share exercise price of $6.97, the closing trading price on July 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS\u2019 offers of employment. Each option has a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the employee\u2019s first date of employment and the remainder vesting in equal monthly installments for thirty-six months … Continue reading "SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-02T21:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-08-02T21:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"wordCount\":312,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\",\"name\":\"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==\",\"datePublished\":\"2021-08-02T21:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","og_locale":"en_US","og_type":"article","og_title":"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ:\u00a0SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS common stock at a per share exercise price of $6.97, the closing trading price on July 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS\u2019 offers of employment. Each option has a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the employee\u2019s first date of employment and the remainder vesting in equal monthly installments for thirty-six months … Continue reading \"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-02T21:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2021-08-02T21:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"wordCount":312,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","name":"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==","datePublished":"2021-08-02T21:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE0MyM0MzM2ODMyIzUwMDA3MDcxOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521689"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521689\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}